Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169347 | 0.95 | PKM (0.65) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL265611 | 0.89 | PKM (0.61) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL2448500 | 0.85 | PKM (0.70) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL6557849 | 0.84 | USP2 (0.53) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL436674 | 0.83 | PKM (0.89) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL15945283 | 0.81 | KMT2A (0.86) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL5564371 | 0.81 | KMT2A (0.86) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL11605844 | 0.81 | PKM (0.63) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL31476293 | 0.81 | ALDH1A1 (0.92) | PKMALDH1A1POLBHTTKMT2A | |
| SCHEMBL7645597 | 0.81 | KMT2A (0.86) | PKMALDH1A1POLBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9669031-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | PKM 383/4885ALDH1A1 4285/4885POLB 1271/4885 |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | PKM 383/4885ALDH1A1 4285/4885POLB 1271/4885 |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | PKM 383/4885ALDH1A1 4285/4885POLB 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.